CoChat

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Purpose: The programmed death-1 ligand/programmed death-1 (PD-L/PD-1) pathway has been recently suggested to play a pivotal role in the immune evasion of tumors from host immune system. In this study, we tried to reveal the clinical importance and therapeutic potential of the PD-L/PD-1 pathway in pancreatic cancer, which is one of the most aggressive and intractable malignant tumors. Experimental Design: We used immunohistochemistry to investigate PD-L expression in 51 patients with pancreatic cancer who underwent surgery and explored the therapeutic efficacy of blocking the PD-L1/PD-1 pathway in murine pancreatic cancer in vivo. Results: PD-L1–positive patients had a significantly poorer prognosis than the PD-L1–negative patients, whereas there was no significant correlation of tumor PD-L2 expression with patient survival. PD-L1 expression was inversely correlated with tumor-infiltrating T lymphocytes, particularly CD8+ T cells. These clinical data have suggested that the PD-L1/PD-1 pathway may be a critical regulator in human pancreatic cancer. Monoclonal antibodies against PD-L1 or PD-1 induced a substantial antitumor effect on murine pancreatic cancer in vivo. PD-L1 blockade promoted CD8+ T-cell infiltration into the tumor and induced local immune activation. Furthermore, the combination of anti–PD-L1 monoclonal antibody and gemcitabine exhibited a significant synergistic effect on murine pancreatic cancer and resulted in complete response without overt toxicity. Conclusion: Our data suggest for the first time that PD-L1 status may be a new predictor of prognosis for patients with pancreatic cancer and provide the rationale for developing a novel therapy of targeting the PD-L/PD-1 pathway against this fatal disease.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-2746

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 901

Metadata

Authors
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., & Nakajima, Y.
Affiliations
  • 1Department of Surgery,
  • 2Second Department of Internal Medicine,
  • Nara Medical University (JP)
  • 4Department of Immunology, Juntendo University School of Medicine; and
  • Tokyo Medical and Dental University (JP)
Venue
Clinical Cancer Research
Published
2007-04-01
Volume
13
Issue
7
Pages
2151-2157
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2161558877
Cited by
889
References
31
Citations by year
2026: 8 · 2025: 22 · 2024: 22 · 2023: 54 · 2022: 47 · 2021: 63 · 2020: 70 · 2019: 71 · 2018: 71 · 2017: 100 · 2016: 79 · 2015: 73 · 2014: 59 · 2013: 35 · 2012: 31
FWCI
9.20
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-L1, PD-1, PD-L2, pancreatic cancer, tumor immune evasion, tumor-infiltrating T cells, CD8+ T cells, prognosis, anti-PD-L1 monoclonal antibody, gemcitabine combination therapy, immune checkpoint blockade
MeSH terms
Gemcitabine, Adenocarcinoma, Aged, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Immunohistochemistry, Male, Mice, Inbred C57BL, Middle Aged, Pancreatic Neoplasms, Peptides, Prognosis, Biomarkers, Tumor, Antigens, CD, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Reverse Transcriptase Polymerase Chain Reaction, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-2746
The paper
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., & Nakajima, Y. (2007). Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-2746

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.